Brokerages predict that Heska Corp (NASDAQ:HSKA) will announce earnings per share (EPS) of $0.35 for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Heska’s earnings. The lowest EPS estimate is $0.32 and the highest is $0.37. Heska posted earnings of $0.40 per share in the same quarter last year, which would indicate a negative year over year growth rate of 12.5%. The business is scheduled to report its next earnings report on Thursday, November 1st.

On average, analysts expect that Heska will report full-year earnings of $1.67 per share for the current financial year, with EPS estimates ranging from $1.62 to $1.72. For the next year, analysts expect that the firm will report earnings of $2.00 per share, with EPS estimates ranging from $1.99 to $2.00. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Heska.

Heska (NASDAQ:HSKA) last posted its quarterly earnings results on Tuesday, August 7th. The medical research company reported $0.24 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.17 by $0.07. Heska had a net margin of 4.67% and a return on equity of 11.49%. The firm had revenue of $29.66 million for the quarter, compared to the consensus estimate of $30.19 million.

HSKA has been the topic of a number of recent research reports. TheStreet upgraded shares of Heska from a “c+” rating to a “b-” rating in a research note on Thursday, May 31st. Benchmark lifted their price target on shares of Heska from $120.00 to $143.00 and gave the stock a “buy” rating in a research note on Monday, May 21st. They noted that the move was a valuation call. Canaccord Genuity reiterated a “buy” rating and set a $123.00 price target (up previously from $115.00) on shares of Heska in a research note on Friday, June 15th. ValuEngine upgraded shares of Heska from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Finally, BidaskClub downgraded shares of Heska from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 22nd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $107.50.

HSKA traded up $2.41 during trading on Monday, reaching $105.02. 30,581 shares of the company’s stock were exchanged, compared to its average volume of 30,569. Heska has a fifty-two week low of $56.59 and a fifty-two week high of $111.34. The company has a market capitalization of $769.35 million, a P/E ratio of 50.73 and a beta of 0.52.

In other news, COO Jason A. Napolitano sold 1,200 shares of the business’s stock in a transaction on Monday, July 9th. The shares were sold at an average price of $110.00, for a total value of $132,000.00. The sale was disclosed in a filing with the SEC, which is available at this link. Also, EVP Steven M. Eyl sold 33,351 shares of the business’s stock in a transaction on Monday, August 13th. The shares were sold at an average price of $98.49, for a total transaction of $3,284,739.99. Following the completion of the sale, the executive vice president now owns 15,401 shares in the company, valued at approximately $1,516,844.49. The disclosure for this sale can be found here. Insiders sold a total of 52,778 shares of company stock worth $5,282,310 in the last 90 days. 14.70% of the stock is owned by corporate insiders.

Large investors have recently modified their holdings of the company. Piedmont Investment Advisors LLC acquired a new stake in shares of Heska in the 2nd quarter valued at $162,000. SG Americas Securities LLC acquired a new stake in shares of Heska in the 2nd quarter valued at $191,000. Paloma Partners Management Co acquired a new stake in shares of Heska in the 2nd quarter valued at $228,000. Macquarie Group Ltd. acquired a new stake in shares of Heska in the 2nd quarter valued at $234,000. Finally, Raymond James Trust N.A. acquired a new stake in shares of Heska in the 2nd quarter valued at $240,000. Institutional investors own 89.17% of the company’s stock.

Heska Company Profile

Heska Corporation manufactures, sells, and markets veterinary diagnostic and specialty products for canine and feline healthcare markets in the United States, Canada, Europe, and internationally. The company's Core Companion Animal Health segment offers Element DC and DRI-CHEM 7000 veterinary chemistry analyzers for blood chemistry and electrolyte analysis; HT5 and HEMATRUE veterinary hematology analyzers to measure blood cell and platelet count, and hemoglobin levels; Element POC blood gas and electrolyte analyzers; COAG veterinary analyzers; Element i immunodiagnostic analyzers; and IV infusion pumps.

Read More: Trading Strategy Examples and Plans

Get a free copy of the Zacks research report on Heska (HSKA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.